Artificial Intelligence With Determination of Central Venous Catheter Line Associated Infection Risk

NCT ID: NCT05914571

Last Updated: 2023-06-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2023-07-31

Study Completion Date

2024-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this methodological, retrospective and prospective study is to; it is a tool to develop a risk estimator tool to detect risk gaps in individuals using artificial intelligence technology that is dangerous for those with CVC in adult intensive care patients, to test risk level estimation frameworks and to evaluate outcomes in the clinic. In our study, it is also our aim to protect, to present the security measures to prevent the risk of CVC with an artificial intelligence model, in an evidence-based way.

The main question\[s\]it aims to answer are:

* Can the risk of CVC-related infection be determined in adult intensive care patients using artificial intelligence?
* To what degree of accuracy can the risk of CVC-associated infection be determined in adult intensive care patients using artificial intelligence?
* What are the nursing practices that can reduce the risk of CVC-related infections?

Methodology to develop an artificial intelligence-based CVC-associated infection risk level determination algorithm, retrospective using data from Electronic Health Records (EHR) patient data and manual patient files between January 2018 and December 2022 to create the algorithm and test the model accuracy, and the development stages of the model After the completion of the model, up-to-date data were collected for the use of the model and it was planned to be done prospectively.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The applications of artificial intelligence-based technologies in nursing are still in their infancy, and it is emphasized that nurses have limited participation in these processes. We think that our study will be supportive in determining the focal points in the clinical practice of nurses in terms of determining the risk level and will contribute to the development of patient goals. It is also important in terms of creating evidence for making the effects of nursing practices visible. In this context, the aim of our study is to develop a risk estimation tool to determine the risk levels of individuals in terms of CVC-related infection in adult intensive care patients by using artificial intelligence technology, to test the accuracy of the risk level estimation and to apply the tool to evaluate the results in the clinic. In addition, our secondary aim is to present the effects of nursing care in preventing the risk of CVC-related infection with the artificial intelligence model in an evidence-based manner.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Artificial Intelligence Central Venous Catheter Associated Bloodstream Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

OTHER

Study Time Perspective

RETROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Received at least 48 hours of treatment in the GICU,
* Age ≥ 18,
* CVC inserted,
* No existing infection before hospitalization, patient data will be included in the dataset for designing and training the artificial intelligence model.

Exclusion Criteria

* Age \<18,
* Those receiving immunosuppressive therapy,
* Those with multiple organ failure,
* Patients undergoing organ transplantation,
* Patients with a diagnosis of chronic kidney failure, will not be included in the dataset.
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Saglik Bilimleri Universitesi

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OTCELEBİ

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.